Search Results | Blood | American Society of Hematology

1-20 of 1134

2 3 4 5

Sort by

Sort Order Select

Journal Articles

HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis

Blood blood.2021011281.

DOI: https://doi.org/10.1182/blood.2021011281

Published: 2021

Journal Articles

Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen–mismatched donors

Brian Kornblit, Barry E. Storer, Niels S. Andersen, Michael B. Maris, Thomas R. Chauncey, Effie W. Petersdorf, Ann E. Woolfrey, Mary E. D. Flowers, Rainer Storb, David G. Maloney, Brenda M. Sandmaier

Blood (2020) 136 (13): 1499–1506.

DOI: https://doi.org/10.1182/blood.2020005338

Published: 2020

Includes: Supplemental data

Journal Articles

The Path to Cure: Using Haploidentical (haplo) Donors and High-Dose Post-Transplant Cyclophosphamide (PTCy) for Treatment-Naïve and Refractory Severe Aplastic Anemia (SAA)

Amy E. DeZern, MD, Marianna Zahurak, MS, Kenneth R. Cooke, MD, David Margolis, MD, Richard J. Jones, MD, Robert A. Brodsky, MD

Blood (2019) 134 (Supplement_1): 147.

DOI: https://doi.org/10.1182/blood-2019-121900

Published: 2019

Journal Articles

Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation from HLA-Identical Sibling Donors: A Retrospective Analysis from the Acute Leukemia Working Party of the EBMT

Blood (2019) 134 (Supplement_1): 148.

DOI: https://doi.org/10.1182/blood-2019-123269

Published: 2019

Journal Articles

Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) As Graft-Vs-Host Disease (GVHD) Prophylaxis after Nonmyeloablative (NMA) Hematopoietic Cell Transplantation (HCT) Using HLA Class I or Class II Antigen Mismatched Donors: Results from a Phase II Multi-Center Trial

Brian Kornblit, MD PhD, Barry Storer, Michael B. Maris, MD, Niels Smedegaard Andersen, MD PhD, Thomas R. Chauncey, MD PhD, Effie W. Petersdorf, MD, Ann Woolfrey, MD, David G. Maloney, MD PhD, Rainer Storb, MD, Brenda M Sandmaier, MD

Blood (2019) 134 (Supplement_1): 369.

DOI: https://doi.org/10.1182/blood-2019-123196

Published: 2019

Journal Articles

Outcomes in Pediatric Patients with Severe Aplastic Anemia Treated with Standard Immunosuppression and Eltrombopag

Emma M. Groarke, MD, Bhavisha A Patel, MD, Carrie Diamond, MD, Fernanda Gutierrez-Rodrigues, PhD, Alana Vicente, MD, Olga Rios, RN, Jennifer Lotter, PA-C, Daniela Baldoni, Ruba Shalhoub, Colin Wu, PhD, Neal S. Young, MD

Blood (2019) 134 (Supplement_1): 454.

DOI: https://doi.org/10.1182/blood-2019-124811

Published: 2019

Journal Articles

Combination of Haploidentical Hematopoietic with Low-Dose ATG, Ptcy and Cord Blood Competitive Transplantation for Hematologic Malignancies

Yiling Chen, Xiaofan Li, MD PhD, Zhenshu Xu, MD, Chen Yuanzhong, MD PhD, Nainong LI

Blood (2019) 134 (Supplement_1): 5734.

DOI: https://doi.org/10.1182/blood-2019-127624

Published: 2019

Journal Articles

Sporadic Late Onset Nemaline Myopathy with a Monoclonal Gammopathy: Comparative Effectiveness of Immuno- and Chemotherapy

David Susman, BMSc, Jesse McLean, PhD, Rouslan Kotchetkov, MD PhD

Blood (2019) 134 (Supplement_1): 5820.

DOI: https://doi.org/10.1182/blood-2019-123817

Published: 2019

Journal Articles

Less Chronic Graft-Versus-Host Disease, Immunosuppressive Therapy and Better Survival after Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplant Recipients: Longer Follow-up of a Multicentre Cell Therapy Transplant Canada Randomized Trial

Jean Roy, MD, Tony Panzarella, M.Sc., P.Stat, Stephen Couban, MDBSc, Félix Couture, MD FRCPC, Gerald M. Devins, PhD, Mohamed Elemary, MD, Stephen Ronan Foley, MD FRCPC, Genevieve Gallagher, MD, John Kuruvilla, MD, Stephanie J. Lee, MD MPH, John Moore, MDFRACP,FRCPA, Thomas J Nevill, MD, Gizelle Popradi, MD FRCP, Kirk R. Schultz, MD, David Szwajcer, MD FRCPC, Cynthia L Toze, MD FRCPC, Irwin Walker, MBBS, FRCPC

Blood (2019) 134 (Supplement_1): 875.

DOI: https://doi.org/10.1182/blood-2019-123275

Published: 2019

Journal Articles

Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation

Hassan Awada, Reda Z. Mahfouz, MD PhD, Jibran Durrani, Ashwin Kishtagari, MBBS, Deepa Jagadeesh, MDMPH, Alan Lichtin, MD, Brian T. Hill, MD, Betty K. Hamilton, MD, Hetty E. Carraway, MD MBA, Navneet S. Majhail, MD MS, Ronald Sobecks, MD, Valeria Visconte, PhD, Matt Kalaycio, MD, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 1226.

DOI: https://doi.org/10.1182/blood-2019-130167

Published: 2019

Journal Articles

Next-Generation Sequencing of HLA Loci Identifies Predisposing and Protective Factors for Immune-Mediated Thrombotic Thrombocytopenic Purpura in a Japanese Population

Kazuya Sakai, MD, Masataka Kuwana, Hiroto Kojima, Hidenori Tanaka, Masayuki Kubo, Hideo Yagi, Masanori Matsumoto

Blood (2019) 134 (Supplement_1): 1085.

DOI: https://doi.org/10.1182/blood-2019-123927

Published: 2019

Journal Articles

Outcomes of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning Regimen in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide for Acute Lymphoblastic Leukemia: ALWP of the EBMT Study

Bhagirathbhai Dholaria, MBBS, Myriam Labopin, MD, Emanuele Angelucci, MD, Johanna Tischer, MD, Mutlu Arat, MD, Fabio Ciceri, MD, Zafer Gülbas, MD, Hakan Ozdogu, MD, Simona Sica, MD, Jose L. Diez-Martin, MD PhD, Yener Koc, MD, Jane Apperley, MB, ChB, MD, Gerard Socie, MD PhD, Sebastian Giebel, MD PhD, Bipin N. Savani, MD, Arnon Nagler, MD MSc, Mohamad Mohty, MD PhD

Blood (2019) 134 (Supplement_1): 320.

DOI: https://doi.org/10.1182/blood-2019-122258

Published: 2019

Journal Articles

Patients Lacking a KIR-Ligand of HLA Group C1 or C2 Have a Lower Incidence of Grades II-IV Acute Graft-Vs-Host Disease after Umbilical Cord Blood Transplantation

Ting Ting Fang, Xiang Wan, Xiaoyu Zhu, Baolin Tang, Kaidi Song, Guangyu Sun, Huilan Liu, Xinchen Fang, Zimin Sun

Blood (2019) 134 (Supplement_1): 3284.

DOI: https://doi.org/10.1182/blood-2019-129961

Published: 2019

Journal Articles

Post-Transplant Cyclophosphamide for Gvhd Prophylaxis in Matched Unrelated Donor Transplantation Compared to ATG-Based Prophylaxis

Rebeca Bailén, MD, Mi Kwon, MD, Maria Jesus Pascual-Cascon, Anna Torrent, Christelle M Ferra, Jaime Sanz, MD PhD, Alberto Doblas-Marquez, Olga Benítez, MD, Jose Luis Piñana Sanchez, Gillen Oarbeascoa, MD, Nieves Dorado, MD, Muñoz Cristina, Carolina Martínez-Laperche, Javier Anguita, MD PhD, Ismael Buño, PhD, José Luis Díez-Martín, MD PhD

Blood (2019) 134 (Supplement_1): 3285.

DOI: https://doi.org/10.1182/blood-2019-124849

Published: 2019

Journal Articles

Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Classical Hodgkin Lymphoma (cHL):a Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

Sairah Ahmed, MD, Nilanjan Ghosh, MD PhD, Manoj Khanal, Kwang Woo Ahn, PhD, Carlos Litovich, MPH, Timothy S. Fenske, MD, Mohamed A Kharfan-Dabaja, MDMBA, Anna Sureda, MD PhD, Mehdi Hamadani, MD

Blood (2019) 134 (Supplement_1): 3318.

DOI: https://doi.org/10.1182/blood-2019-121848

Published: 2019

Journal Articles

Immune Reconstitution after Allogeneic Hematopoietic Cell Transplantation: Comparing Post-Transplant Cyclophosphamide Versus Anti-T-Lymphocyte Globulin As Graft-Versus-Host Disease Prophylaxis in a Retrospective Cohort Study

Rashit Bogdanov, PhD, Saskia Leserer, Evren Bayraktar, PhD, Nikolaos Tsachakis-Mück, Lara Kasperidus, PhD, Markus Ditschkowski, PhD, Dietrich W. Beelen, Amin T. Turki, MD PhD

Blood (2019) 134 (Supplement_1): 3289.

DOI: https://doi.org/10.1182/blood-2019-130623

Published: 2019

Journal Articles

Prognostic Value of Lymphopenia and Lymphocytosis after Peripheral Blood Haplo-Identical Stem Cell Transplantation

Yannick LE Bris, PharmD, Thierry Guillaume, MD PhD, Camille Debord, PharmD, Pierre Peterlin, Soraya Wuilleme, PharmD, PhD, Céline Bressollette, MD PhD, Amandine Le Bourgeois, MD, Alice Garnier, MD, Aurélie Fantou, PharmD, Marie Audrain, MD PhD, Audrey Ménard, Nelly Robillard, PhD, Marion Eveillard, Steven Le Gouill, Berthe Marie Imbert, PharmD, PhD, Marie C Bene, PharmSciD, PhD, Patrice Chevallier, MD

Blood (2019) 134 (Supplement_1): 3319.

DOI: https://doi.org/10.1182/blood-2019-122093

Published: 2019

Journal Articles

Shortened Immunosuppression Following Peripheral Blood (PB) Haploidentical (haplo) Transplantation with Post-Transplant Cyclophosphamide (PTCy) Is Associated with Tolerable Rates of Graft-Vs-Host Disease (GVHD)

Amy E. DeZern, MD, Marianna Zahurak, MS, Javier Bolanos-Meade, MD, Richard J. Jones, MD

Blood (2019) 134 (Supplement_1): 3320.

DOI: https://doi.org/10.1182/blood-2019-122762

Published: 2019

Journal Articles

Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor

Blood (2019) 134 (Supplement_1): 3323.

DOI: https://doi.org/10.1182/blood-2019-125865

Published: 2019

Journal Articles

Impact of HLA Class I Allele Mismatch on Viral Infection within 100 Days after Cord Blood Transplantation

Tomoki Iemura, MD, Yasuyuki Arai, MD PhD, Junya Kanda, MD, Toshio Kitawaki, MD PhD, Masakatsu Hishizawa, MD PhD, Tadakazu Kondo, MD PhD, Kouhei Yamashita, MD PhD, Akifumi Takaori-Kondo, MD PhD

Blood (2019) 134 (Supplement_1): 3267.

DOI: https://doi.org/10.1182/blood-2019-123073

Published: 2019

2 3 4 5

NARROW

HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis

Sirolimus with CSP and MMF as GVHD prophylaxis for allogeneic transplantation with HLA antigen–mismatched donors

The Path to Cure: Using Haploidentical (haplo) Donors and High-Dose Post-Transplant Cyclophosphamide (PTCy) for Treatment-Naïve and Refractory Severe Aplastic Anemia (SAA)

Post-Transplant Cyclophosphamide Versus Antithymocyte Globulin in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation from HLA-Identical Sibling Donors: A Retrospective Analysis from the Acute Leukemia Working Party of the EBMT

Sirolimus Combined with Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) As Graft-Vs-Host Disease (GVHD) Prophylaxis after Nonmyeloablative (NMA) Hematopoietic Cell Transplantation (HCT) Using HLA Class I or Class II Antigen Mismatched Donors: Results from a Phase II Multi-Center Trial

Outcomes in Pediatric Patients with Severe Aplastic Anemia Treated with Standard Immunosuppression and Eltrombopag

Combination of Haploidentical Hematopoietic with Low-Dose ATG, Ptcy and Cord Blood Competitive Transplantation for Hematologic Malignancies

Sporadic Late Onset Nemaline Myopathy with a Monoclonal Gammopathy: Comparative Effectiveness of Immuno- and Chemotherapy

Less Chronic Graft-Versus-Host Disease, Immunosuppressive Therapy and Better Survival after Anti-Thymocyte Globulin in Unrelated Donor Stem Cell Transplant Recipients: Longer Follow-up of a Multicentre Cell Therapy Transplant Canada Randomized Trial

Long-Term Experience with Large Granular Lymphocytic Leukemia Evolving after Solid Organ and Hematopoietic Stem Cell Transplantation

Next-Generation Sequencing of HLA Loci Identifies Predisposing and Protective Factors for Immune-Mediated Thrombotic Thrombocytopenic Purpura in a Japanese Population

Outcomes of Total Body Irradiation- Versus Chemotherapy-Based Myeloablative Conditioning Regimen in Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide for Acute Lymphoblastic Leukemia: ALWP of the EBMT Study

Patients Lacking a KIR-Ligand of HLA Group C1 or C2 Have a Lower Incidence of Grades II-IV Acute Graft-Vs-Host Disease after Umbilical Cord Blood Transplantation

Post-Transplant Cyclophosphamide for Gvhd Prophylaxis in Matched Unrelated Donor Transplantation Compared to ATG-Based Prophylaxis

Comparison of Reduced-Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Classical Hodgkin Lymphoma (cHL):a Center for International Blood & Marrow Transplant Research (CIBMTR) Analysis

Immune Reconstitution after Allogeneic Hematopoietic Cell Transplantation: Comparing Post-Transplant Cyclophosphamide Versus Anti-T-Lymphocyte Globulin As Graft-Versus-Host Disease Prophylaxis in a Retrospective Cohort Study

Prognostic Value of Lymphopenia and Lymphocytosis after Peripheral Blood Haplo-Identical Stem Cell Transplantation

Shortened Immunosuppression Following Peripheral Blood (PB) Haploidentical (haplo) Transplantation with Post-Transplant Cyclophosphamide (PTCy) Is Associated with Tolerable Rates of Graft-Vs-Host Disease (GVHD)

Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor

Impact of HLA Class I Allele Mismatch on Viral Infection within 100 Days after Cord Blood Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only